Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi (OPTI) has finalized a supply agreement with Bloom Psychedelic Therapy and Research Centre
  • Optimi will supply Bloom with sufficient biomass of natural psilocybin to begin conducting its clinical trial in partnership at the University of Calgary
  • Bloom is a Calgary-based provider of mental health services, including psychedelic-assisted therapies employing ketamine treatments
  • Optimi Health focuses on producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms for the health and wellness markets
  • Optimi Health Corp. (OPTI) is trading steady at C$0.40 per share at 10:35 am ET

Optimi (OPTI) has finalized a supply agreement with Bloom Psychedelic Therapy and Research Centre.

Optimi will supply Bloom with sufficient biomass of natural psilocybin to begin conducting its clinical trial in partnership with the IMPACT Clinical Trial Accelerator Program at the University of Calgary.

Optimi Health CEO, Bill Ciprick called this supply agreement with Bloom another key relationship for for his company.

“Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”

Bloom Founder and CEO Jim Parker added that the partnership provides an opportunity to measure true GMP-produced, Canadian-sourced natural psilocybin.

“Regulatory bodies in Canada and across the world are watching Canada’s fledgling psychedelics industry and how it performs in quality, safety, and efficacy,” said Parker. “So, I see this as an early watershed moment where good therapeutic practices, combined with Optimi’s Canadian-GMP-grade natural psilocybin, could establish Canada as a real leader amongst those wanting to learn from us.”

Bloom is a Calgary-based provider of mental health services, including psychedelic-assisted therapies employing ketamine treatments.

Optimi Health focuses on producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms for the health and wellness markets.

Optimi Health Corp. (OPTI) is trading steady at C$0.40 per share at 10:35 am ET.

More From The Market Herald
Medicenna - President and CEO, Fahar Merchant.

" Medicenna (TSX:MDNA) closes US$20 million public offering

Medicenna Therapeutics Corp. (MDNA) has closed its

" Titan Medical (TSX:TMD) reports Q2 2022 financial results

Titan Medical (TMD) released financial results for the three and six months ended June 30, 2022.

" The Gummy Project (CSE:GUMY) launch new investor relations website

The Gummy Project (GUMY) is launching its new investor relations website at shopgummies.com/pages/investors.
The Market Herald Video

" Alkaline (NEO:PWWR) to develop fuel cells for off-grid and back-up generator markets

Alkaline Fuel Cell Power (PWWR) is supplementing its 4-kW combined heat and power fuel cell development.